Antithrombin III for critically ill patients
Antithrombin III (AT III) cannot be recommended for critically ill patients based on the available evidence.
Critical illness is associated with uncontrolled inflammation and vascular damage which can result in multiple organ failure and death. AT III is an anticoagulant with anti-inflammatory properties but the efficacy and any harmful effects of AT III supplementation in critically ill patients are unknown. This review assesses the benefits and harms of AT III in critically ill patients.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.